Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP-COVID)

整体项目总结 遏制新冠肺炎的传播将需要跨基础、翻译和应用的研究 科学。血清学检测中心将改善新冠肺炎大流行的结果(停止- COVID)被提议作为一个跨学科实体，以了解暴露风险、传播、 免疫反应、疾病严重程度、保护和检测/接种障碍，目标是改善 人口健康和临床结果。该中心将利用最先进的血清学和分子检测技术， 在俄亥俄州立大学对急救人员的纵向研究中，开发了一组持续高危的SARS-CoV-2 暴露，以及他们的家庭接触。通过拟议的工作，Stop-COVID调查人员将 了解以下关键方面：(I)在无症状和有症状的个人中传播，(Ii)免疫， 疾病结局的病毒决定因素，以及(3)与免疫保护相关的因素。中心 调查人员还将确定传达检测结果和有关新冠肺炎信息的最佳做法 提高对风险、传播和保护的了解，同时减少检测的准入障碍。 STOP-COVID中心将：目标1通过三个共享资源发展研究所基础设施 核心：1.提供全面指导和领导、协调中心所有活动的行政核心 以及项目-核心-SeroNet交互；2.测试和生物库核心，其角色是执行 在我们的纵向研究中使用高通量ELISA法和中和法进行第一级血清学和病毒检测 由俄亥俄州立大学开发并由俄亥俄州立大学分担成本的分析；以及3.数据管理和分析核心 为项目调查人员提供集中的生物统计、生物信息学、流行病学和 心理测量学专业知识。目标2：开展三个创新研究项目：项目1：并行 血清学和病毒检测以确定新冠肺炎的流行率、传播和保护 应答者队列。该项目还将生成疫苗或单抗的血清学数据，一旦可用 可能是高优先组；项目2：新冠肺炎严重程度和 免疫保护。该项目将评估新冠肺炎在SARS-CoV-2背景下的血清学反应 和普通感冒冠状病毒(CCCoV)抗体，使用针对一组抗原的新方法。项目2还 将利用转录组学来了解宿主遗传学、CCCoV、其他呼吸道病毒和免疫 反应有助于发病；和项目3：对不断变化的血清学和病毒信息作出反应 在新冠肺炎附近。该项目将结合项目1和2以及SeroNet的结果，以提供最佳实践 在风险沟通中，提供行为指导以减少传播，并加强对 疾病。目标3：SeroNet参与和共享数据和最佳做法。我们将利用Stop-COVID 与SeroNet共享数据、结果、试剂和最佳实践的基础设施，这将推动新的发现 并将其转化为可操作的战略，以便在所有受新冠肺炎影响的群体中实施。

Overall Project Summary Stemming the spread of COVID-19 will require research that cross-cuts basic, translational, and applied sciences. The Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP- COVID) is proposed as a transdisciplinary entity to understand the interface between exposure risk, transmission, immune responses, disease severity, protection, and barriers to testing/vaccination, with the goal of improving population health and clinical outcomes. The Center will utilize state-of-the-art serological and molecular tests, developed at OSU, in a longitudinal study of first responders, a group at continual high risk of SARS-CoV-2 exposure, as well as their household contacts. Through the proposed work, STOP-COVID investigators will understand critical aspects of: (i) transmission in both asymptomatic and symptomatic individuals, (ii) immune, host, and viral determinants of disease outcome, and (iii) factors associated with immune protection. Center investigators will also identify best practices for communication of test results and information about COVID-19 to improve understanding of risk, transmission, and protection, while reducing access barriers to testing. The Center to STOP-COVID will: Aim 1 Develop Institute Infrastructure through three shared resource cores: 1. An Administrative Core that provides overall direction and leadership, coordinating all Center activities as well as Project–Core–SeroNet interactions; 2. A Testing and Biorepository Core, whose role is to perform first-tier serologic and viral testing during our longitudinal study using high throughput ELISA and neutralization assays developed at OSU, and cost-shared by OSU; and 3. A Data Management and Analysis Core that will provide project investigators with a centralized resource for biostatistics, bioinformatics, epidemiology, and psychometrics expertise. Aim 2: Conduct three innovative research projects to address: Project 1: Parallel serological and viral testing to determine COVID-19 prevalence, transmission, and protection in extended first responder cohorts. This project will also generate serology data for vaccines or mAbs, once available to this presumably high-priority group; Project 2: Serologic and molecular determinants of COVID-19 severity and immune protection. This project will evaluate COVID-19 serological responses in the context of SARS-CoV-2 and common cold CoV (CCCoV) antibodies, using novel assays specific for a panel of antigens. Project 2 also will employ transcriptomics to understand how host genetics, CCCoV, other respiratory viruses, and immune responses contribute to pathogenesis; and Project 3: Responding to changing serological and viral information around COVID-19. This project will incorporate results from Projects 1 & 2 and SeroNet to inform best practices in risk communication, provide behavioral guidance to decrease transmission, and enhance protection from disease. Aim 3: SeroNet Participation and Sharing of Data and Best Practices. We will leverage STOP-COVID infrastructure to share data, results, reagents, and best practices with SeroNet, which will drive new discoveries and their translation into actionable strategies for implementation across all groups affected by COVID-19.